Noile-Immune Biotech Inc. (TYO:4893)

Japan flag Japan · Delayed Price · Currency is JPY
152.00
0.00 (0.00%)
At close: Mar 6, 2026
Market Cap6.58B -19.1%
Revenue (ttm)5.00M -28.6%
Net Income-793.00M
EPS-18.31
Shares Out43.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume86,700
Average Volume522,925
Open154.00
Previous Close152.00
Day's Range151.00 - 155.00
52-Week Range120.00 - 214.00
Beta-0.35
RSI48.26
Earnings DateFeb 13, 2026

About Noile-Immune Biotech

Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company’s product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, an autologous CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 25
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4893
Full Company Profile

Financial Performance

In 2025, Noile-Immune Biotech's revenue was 5.00 million, a decrease of -28.57% compared to the previous year's 7.00 million. Losses were -793.00 million, -17.74% less than in 2024.

Financial Statements